Taysha gene therapies to participate in upcoming april investor healthcare conferences

Dallas--(business wire)--taysha gene therapies, inc. (nasdaq: tsha), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing aav-based gene therapies for the treatment of monogenic diseases of the central nervous system (cns) in both rare and large patient populations, today announced its participation in upcoming fireside chats at the guggenheim genomic medicines and rare disease day conference and the 21st annual needham virtual healthcare conference. c
TSHA Ratings Summary
TSHA Quant Ranking